PropertyValue
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/ns/prov#value
  • Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca treating various tumor types including BRCA-mutated breast and ovarian cancers.
http://www.w3.org/ns/prov#wasQuotedFrom
  • biopharminternational.com